Identification

Name
Deflazacort
Accession Number
DB11921
Type
Small Molecule
Groups
Approved
Description

Deflazacort is a glucocorticoid used as an anti-inflammatory and immunosuppressant. It was approved in February, 2017 by the FDA for use in treatment of Duchenne muscular dystrophy (trade name Emflaza).

Structure
Thumb
Synonyms
Not Available
External IDs
MDL 458 / MDL-458
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
EmflazaTablet6 mg/1OralMarathon Pharmaceuticals2017-02-09Not applicableUs
EmflazaTablet36 mg/1OralMarathon Pharmaceuticals2017-02-09Not applicableUs
EmflazaTablet18 mg/1OralMarathon Pharmaceuticals2017-02-09Not applicableUs
EmflazaSuspension22.75 mg/mLOralMarathon Pharmaceuticals2017-02-09Not applicableUs
EmflazaTablet30 mg/1OralMarathon Pharmaceuticals2017-02-09Not applicableUs
International/Other Brands
Calcort (Shire) / Cortax / Decortil / Deflanil / MOAID / Xalcort (Beacon Pharmaceuticals Limited) / Zamen
Categories
UNII
KR5YZ6AE4B
CAS number
14484-47-0
Weight
Average: 441.524
Monoisotopic: 441.215137722
Chemical Formula
C25H31NO6
InChI Key
FBHSPRKOSMHSIF-GRMWVWQJSA-N
InChI
InChI=1S/C25H31NO6/c1-13-26-25(20(30)12-31-14(2)27)21(32-13)10-18-17-6-5-15-9-16(28)7-8-23(15,3)22(17)19(29)11-24(18,25)4/h7-9,17-19,21-22,29H,5-6,10-12H2,1-4H3/t17-,18-,19-,21+,22+,23-,24-,25+/m0/s1
IUPAC Name
2-[(1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-6,9,13-trimethyl-16-oxo-5-oxa-7-azapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosa-6,14,17-trien-8-yl]-2-oxoethyl acetate
SMILES
[H][[email protected]@]12C[[email protected]@]3([H])[[email protected]]4([H])CCC5=CC(=O)C=C[[email protected]]5(C)[[email protected]@]4([H])[[email protected]@]([H])(O)C[[email protected]]3(C)[[email protected]@]1(N=C(C)O2)C(=O)COC(C)=O

Pharmacology

Indication

is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older

Structured Indications
Pharmacodynamics

Clinical studies have indicated that the average potency ratio of deflazacort to prednisolone is 0.69–0.89 and 6 mg of deflazacort is equivalent to 5 mg of prednisolone. However, the therapeutic dosage ratio has been reported to range from 1:1.2 to 1:1.5 Due to the short pharmacokinetic half-life of its active metabolite, pharmacodynamic effects of deflazacort are of shorter duration than those of methylprednisolone and prednisolone.

Mechanism of action

Deflazacort is a corticosteroid prodrug, whose active metabolite, 21-desDFZ, acts through the glucocorticoid receptor to exert anti-inflammatory and immunosuppressive effects. The precise mechanism by which deflazacort exerts its therapeutic effects in patients with DMD is unknown.

Absorption

After oral administration in the fasted state, the median Tmax with deflazacort tablets or suspension is about 1 hour (range 0.25 to 2 hours). Food Effect: Co-administration of deflazacort tablets with a high-fat meal reduced Cmax by about 30% and delayed Tmax by one hour, relative to administration under fasting conditions, but there was no effect on the overall systemic absorption as measured by AUC. The administration of deflazacort with food or crushed in applesauce did not affect the absorption and bioavailability of deflazacort. Research findings: The pharmacokinetic parameters of 21-OH DFZ after the single oral administration of 6 mg, 12 mg and 24 mg DFZ tablets were as follows: (37.7 +/- 11.6), (61.5 +/- 17.7) and (123 +/- 23) ng x mL(-1) for C(max); (1.90 +/- 0.32), (1.96 +/- 0.27) and (2.13 +/- 0.34) h for t1/2; (96.6 +/- 25.9), (190 +/- 44) and (422 +/- 107) ng x h x mL(-1) for AUC(0-14 h), respectively. After the multiple dose administration, the mean plasma concentration at steady-state C(av) was (7.00 +/- 1.66) ng x mL(-1) and the degree of plasma concentration fluctuation DF was 7.7 +/- 1.2.

Volume of distribution

Not available

Protein binding

The protein binding of the active metabolite of deflazacort is about 40%.

Metabolism

Deflazacort is rapidly converted to the active metabolite 21-desDFZ by esterases after oral administration. 21-desDFZ is further metabolized by CYP3A4 to several other inactive metabolites.

Route of elimination

Urinary excretion is the predominant route of deflazacort elimination (about 68% of the dose), and the elimination is almost completed by 24 hours post dose. 21-desDFZ accounts for 18% of the eliminated drug in the urine.

Half life

half-life is 1.1 to 1.9 h

Clearance

Not available

Toxicity

The LD50 for the oral dose is greater than 4000 mg/kg in laboratory animals.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Deflazacort is combined with 1,10-Phenanthroline.Experimental
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Deflazacort.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Acemetacin is combined with Deflazacort.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Deflazacort.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Deflazacort.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Deflazacort.Approved, Withdrawn
AldesleukinDeflazacort may decrease the antineoplastic activities of Aldesleukin.Approved
AlmasilateThe bioavailability of Deflazacort can be decreased when combined with Almasilate.Approved, Experimental
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Deflazacort.Experimental
AloglutamolThe bioavailability of Deflazacort can be decreased when combined with Aloglutamol.Experimental
AloxiprinThe risk or severity of adverse effects can be increased when Aloxiprin is combined with Deflazacort.Experimental
AluminiumThe bioavailability of Deflazacort can be decreased when combined with Aluminium.Approved
Aluminium acetoacetateThe bioavailability of Deflazacort can be decreased when combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe bioavailability of Deflazacort can be decreased when combined with Aluminium glycinate.Experimental
Aluminum hydroxideThe bioavailability of Deflazacort can be decreased when combined with Aluminum hydroxide.Approved
AmbenoniumThe risk or severity of adverse effects can be increased when Deflazacort is combined with Ambenonium.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Deflazacort.Approved
AmiodaroneThe metabolism of Deflazacort can be decreased when combined with Amiodarone.Approved, Investigational
Amphotericin BDeflazacort may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Deflazacort.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Deflazacort.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Deflazacort.Approved
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Deflazacort.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Deflazacort.Approved, Investigational
AprepitantThe serum concentration of Deflazacort can be increased when it is combined with Aprepitant.Approved, Investigational
AtazanavirThe metabolism of Deflazacort can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Deflazacort can be decreased when combined with Atomoxetine.Approved
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Deflazacort.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Deflazacort.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Deflazacort.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Deflazacort.Approved, Investigational
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Deflazacort.Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Deflazacort.Experimental
BendroflumethiazideDeflazacort may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Deflazacort.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Deflazacort.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Deflazacort.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Deflazacort.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Deflazacort.Experimental
Bismuth SubcitrateThe bioavailability of Deflazacort can be decreased when combined with Bismuth Subcitrate.Approved
Bismuth subnitrateThe bioavailability of Deflazacort can be decreased when combined with Bismuth subnitrate.Experimental
BoceprevirThe metabolism of Deflazacort can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Deflazacort can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Deflazacort can be decreased when it is combined with Bosentan.Approved, Investigational
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Deflazacort.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Deflazacort.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Deflazacort.Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Deflazacort.Experimental
BumetanideDeflazacort may increase the hypokalemic activities of Bumetanide.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Deflazacort.Approved, Nutraceutical
Calcium CarbonateThe bioavailability of Deflazacort can be decreased when combined with Calcium Carbonate.Approved
Calcium silicateThe bioavailability of Deflazacort can be decreased when combined with Calcium silicate.Experimental
Capromab pendetideDeflazacort may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
CarbamazepineThe metabolism of Deflazacort can be increased when combined with Carbamazepine.Approved, Investigational
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Deflazacort.Approved, Vet Approved, Withdrawn
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Deflazacort.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Deflazacort.Approved, Investigational
CeritinibThe serum concentration of Deflazacort can be increased when it is combined with Ceritinib.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Deflazacort.Approved, Vet Approved
ChlorothiazideDeflazacort may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Deflazacort can be increased when it is combined with Chlorotrianisene.Investigational, Withdrawn
ChlorthalidoneDeflazacort may increase the hypokalemic activities of Chlorthalidone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Deflazacort resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Deflazacort.Approved
CinoxacinThe risk or severity of adverse effects can be increased when Deflazacort is combined with Cinoxacin.Approved, Investigational, Withdrawn
ClarithromycinThe metabolism of Deflazacort can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Deflazacort can be decreased when combined with Clemastine.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Deflazacort.Approved
Clostridium tetani toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Deflazacort.Approved
ClotrimazoleThe metabolism of Deflazacort can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe metabolism of Deflazacort can be decreased when combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Deflazacort resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Deflazacort resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ConivaptanThe serum concentration of Deflazacort can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated estrogensThe serum concentration of Deflazacort can be increased when it is combined with Conjugated estrogens.Approved
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Deflazacort.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Deflazacort.Approved
CoumaphosThe risk or severity of adverse effects can be increased when Deflazacort is combined with Coumaphos.Vet Approved
CrizotinibThe metabolism of Deflazacort can be decreased when combined with Crizotinib.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Deflazacort.Investigational
CyclopenthiazideDeflazacort may increase the hypokalemic activities of Cyclopenthiazide.Experimental
CyclosporineThe metabolism of Deflazacort can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Deflazacort.Investigational
DabrafenibThe serum concentration of Deflazacort can be decreased when it is combined with Dabrafenib.Approved
DaidzeinThe serum concentration of Deflazacort can be increased when it is combined with Daidzein.Experimental
DanazolDeflazacort may increase the fluid retaining activities of Danazol.Approved
DarunavirThe metabolism of Deflazacort can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Deflazacort can be increased when it is combined with Dasatinib.Approved, Investigational
DecamethoniumThe risk or severity of adverse effects can be increased when Deflazacort is combined with Decamethonium.Approved
DeferasiroxThe serum concentration of Deflazacort can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Deflazacort can be decreased when combined with Delavirdine.Approved
DemecariumThe risk or severity of adverse effects can be increased when Deflazacort is combined with Demecarium.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Deflazacort.Approved
dersalazineThe risk or severity of adverse effects can be increased when dersalazine is combined with Deflazacort.Investigational
DichlorvosThe risk or severity of adverse effects can be increased when Deflazacort is combined with Dichlorvos.Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Deflazacort.Approved, Vet Approved
DienestrolThe serum concentration of Deflazacort can be increased when it is combined with Dienestrol.Approved, Investigational
DiethylstilbestrolThe serum concentration of Deflazacort can be increased when it is combined with Diethylstilbestrol.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Deflazacort.Experimental
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Deflazacort.Approved
DihydroergotamineThe metabolism of Deflazacort can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteroneDeflazacort may increase the fluid retaining activities of Dihydrotestosterone.Illicit
DiltiazemThe metabolism of Deflazacort can be decreased when combined with Diltiazem.Approved
DistigmineThe risk or severity of adverse effects can be increased when Deflazacort is combined with Distigmine.Experimental
DonepezilThe risk or severity of adverse effects can be increased when Deflazacort is combined with Donepezil.Approved
DoxycyclineThe metabolism of Deflazacort can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Deflazacort can be decreased when combined with Dronedarone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Deflazacort.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Deflazacort.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Deflazacort.Investigational
EchothiophateThe risk or severity of adverse effects can be increased when Deflazacort is combined with Echothiophate.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when Deflazacort is combined with Edrophonium.Approved
EnoxacinThe risk or severity of adverse effects can be increased when Deflazacort is combined with Enoxacin.Approved, Investigational
EnzalutamideThe serum concentration of Deflazacort can be decreased when it is combined with Enzalutamide.Approved
EpimestrolThe serum concentration of Deflazacort can be increased when it is combined with Epimestrol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Deflazacort.Approved
EquolThe serum concentration of Deflazacort can be increased when it is combined with Equol.Investigational
ErythromycinThe metabolism of Deflazacort can be decreased when combined with Erythromycin.Approved, Vet Approved
EstradiolThe serum concentration of Deflazacort can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Deflazacort can be increased when it is combined with Estriol.Approved, Investigational, Vet Approved
Estrogens, esterifiedThe serum concentration of Deflazacort can be increased when it is combined with Estrogens, esterified.Approved
EstroneThe serum concentration of Deflazacort can be increased when it is combined with Estrone.Approved
Etacrynic acidDeflazacort may increase the hypokalemic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Deflazacort.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Deflazacort.Experimental
Ethinyl EstradiolThe serum concentration of Deflazacort can be increased when it is combined with Ethinyl Estradiol.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Deflazacort.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Deflazacort.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Deflazacort.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Deflazacort.Approved, Investigational
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Deflazacort.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Deflazacort.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Deflazacort.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Deflazacort.Approved
FenthionThe risk or severity of adverse effects can be increased when Deflazacort is combined with Fenthion.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Deflazacort.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Deflazacort.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Deflazacort.Experimental
FingolimodDeflazacort may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FleroxacinThe risk or severity of adverse effects can be increased when Deflazacort is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Deflazacort.Approved, Withdrawn
FluconazoleThe metabolism of Deflazacort can be decreased when combined with Fluconazole.Approved
FlumequineThe risk or severity of adverse effects can be increased when Deflazacort is combined with Flumequine.Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Deflazacort.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Deflazacort.Experimental
FluoxymesteroneDeflazacort may increase the fluid retaining activities of Fluoxymesterone.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Deflazacort.Approved, Investigational
FluvoxamineThe metabolism of Deflazacort can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Deflazacort can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Deflazacort can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Deflazacort can be increased when combined with Fosphenytoin.Approved
FurosemideDeflazacort may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Deflazacort can be increased when it is combined with Fusidic Acid.Approved
G17DTThe therapeutic efficacy of G17DT can be decreased when used in combination with Deflazacort.Investigational
GalantamineThe risk or severity of adverse effects can be increased when Deflazacort is combined with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Deflazacort is combined with Gallamine Triethiodide.Approved
GarenoxacinThe risk or severity of adverse effects can be increased when Deflazacort is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of adverse effects can be increased when Deflazacort is combined with Gatifloxacin.Approved, Investigational
GemifloxacinThe risk or severity of adverse effects can be increased when Deflazacort is combined with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Deflazacort can be increased when it is combined with Genistein.Investigational
GI-5005The therapeutic efficacy of GI-5005 can be decreased when used in combination with Deflazacort.Investigational
GLPG-0492Deflazacort may increase the fluid retaining activities of GLPG-0492.Investigational
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Deflazacort.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when Deflazacort is combined with Grepafloxacin.Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Deflazacort.Experimental
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Deflazacort.Experimental
HexestrolThe serum concentration of Deflazacort can be increased when it is combined with Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Deflazacort.Investigational
Huperzine AThe risk or severity of adverse effects can be increased when Deflazacort is combined with Huperzine A.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Deflazacort.Approved, Investigational
HydrochlorothiazideDeflazacort may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideDeflazacort may increase the hypokalemic activities of Hydroflumethiazide.Approved, Investigational
HydrotalciteThe bioavailability of Deflazacort can be decreased when combined with Hydrotalcite.Experimental, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Deflazacort.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Deflazacort.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Deflazacort.Approved
IdelalisibThe serum concentration of Deflazacort can be increased when it is combined with Idelalisib.Approved
ImatinibThe metabolism of Deflazacort can be decreased when combined with Imatinib.Approved
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Deflazacort.Experimental
IndacaterolIndacaterol may increase the hypokalemic activities of Deflazacort.Approved
IndapamideDeflazacort may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe metabolism of Deflazacort can be decreased when combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Deflazacort.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Deflazacort.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Deflazacort.Withdrawn
INGN 201The therapeutic efficacy of INGN 201 can be decreased when used in combination with Deflazacort.Investigational
INGN 225The therapeutic efficacy of INGN 225 can be decreased when used in combination with Deflazacort.Investigational
IpidacrineThe risk or severity of adverse effects can be increased when Deflazacort is combined with Ipidacrine.Experimental
IsavuconazoniumThe metabolism of Deflazacort can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoflurophateThe risk or severity of adverse effects can be increased when Deflazacort is combined with Isoflurophate.Approved, Investigational, Withdrawn
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Deflazacort.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Deflazacort.Withdrawn
IsradipineThe metabolism of Deflazacort can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Deflazacort can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Deflazacort can be increased when it is combined with Ivacaftor.Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Deflazacort.Experimental
KetoconazoleThe metabolism of Deflazacort can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Deflazacort.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Deflazacort.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Deflazacort is combined with Leflunomide.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when Deflazacort is combined with Levofloxacin.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Deflazacort.Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Deflazacort.Experimental
LopinavirThe metabolism of Deflazacort can be decreased when combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Deflazacort.Approved, Investigational
LovastatinThe metabolism of Deflazacort can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Deflazacort.Approved, Investigational
LuliconazoleThe serum concentration of Deflazacort can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Deflazacort can be increased when combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Deflazacort.Approved, Investigational
MagaldrateThe bioavailability of Deflazacort can be decreased when combined with Magaldrate.Approved, Withdrawn
Magnesium HydroxideThe bioavailability of Deflazacort can be decreased when combined with Magnesium Hydroxide.Approved
Magnesium oxideThe bioavailability of Deflazacort can be decreased when combined with Magnesium oxide.Approved
Magnesium peroxideThe bioavailability of Deflazacort can be decreased when combined with Magnesium peroxide.Experimental
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Deflazacort.Approved
Magnesium silicateThe bioavailability of Deflazacort can be decreased when combined with Magnesium silicate.Approved, Experimental
Magnesium TrisilicateThe bioavailability of Deflazacort can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe risk or severity of adverse effects can be increased when Deflazacort is combined with Malathion.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Deflazacort.Approved, Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Deflazacort.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Deflazacort.Approved
MefloquineThe risk or severity of adverse effects can be increased when Deflazacort is combined with Mefloquine.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Deflazacort.Approved, Vet Approved
MemantineThe risk or severity of adverse effects can be increased when Deflazacort is combined with Memantine.Approved, Investigational
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Deflazacort.Approved
MesteroloneDeflazacort may increase the fluid retaining activities of Mesterolone.Experimental
MestranolThe serum concentration of Deflazacort can be increased when it is combined with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Deflazacort.Investigational, Withdrawn
MethallenestrilThe serum concentration of Deflazacort can be increased when it is combined with Methallenestril.Experimental
Methanesulfonyl FluorideThe risk or severity of adverse effects can be increased when Deflazacort is combined with Methanesulfonyl Fluoride.Investigational
MethyclothiazideDeflazacort may increase the hypokalemic activities of Methyclothiazide.Approved
Methyl salicylateThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Deflazacort.Approved, Vet Approved
MethyltestosteroneDeflazacort may increase the fluid retaining activities of Methyltestosterone.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Deflazacort is combined with Metoclopramide.Approved, Investigational
MetolazoneDeflazacort may increase the hypokalemic activities of Metolazone.Approved
MifepristoneThe serum concentration of Deflazacort can be increased when it is combined with Mifepristone.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Deflazacort is combined with Minaprine.Approved
MitotaneThe serum concentration of Deflazacort can be decreased when it is combined with Mitotane.Approved
MivacuriumMivacurium may increase the adverse neuromuscular activities of Deflazacort.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Deflazacort.Investigational
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Deflazacort.Experimental
MoxestrolThe serum concentration of Deflazacort can be increased when it is combined with Moxestrol.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Deflazacort.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Deflazacort.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Deflazacort.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Deflazacort.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Deflazacort.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when Deflazacort is combined with Nalidixic Acid.Approved, Investigational
NandroloneDeflazacort may increase the fluid retaining activities of Nandrolone.Experimental, Investigational
Nandrolone decanoateDeflazacort may increase the fluid retaining activities of Nandrolone decanoate.Approved, Illicit
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Deflazacort.Approved, Vet Approved
NatalizumabThe risk or severity of adverse effects can be increased when Deflazacort is combined with Natalizumab.Approved, Investigational
NefazodoneThe metabolism of Deflazacort can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Deflazacort can be decreased when combined with Nelfinavir.Approved
NemonoxacinThe risk or severity of adverse effects can be increased when Deflazacort is combined with Nemonoxacin.Investigational
NeostigmineThe risk or severity of adverse effects can be increased when Deflazacort is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Deflazacort.Approved
NetupitantThe serum concentration of Deflazacort can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Deflazacort can be increased when combined with Nevirapine.Approved
NicorandilThe risk or severity of adverse effects can be increased when Deflazacort is combined with Nicorandil.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Deflazacort.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Deflazacort.Approved
NilotinibThe metabolism of Deflazacort can be decreased when combined with Nilotinib.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Deflazacort.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Deflazacort.Investigational
NorfloxacinThe risk or severity of adverse effects can be increased when Deflazacort is combined with Norfloxacin.Approved
OlaparibThe metabolism of Deflazacort can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Deflazacort.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Deflazacort.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Deflazacort.Vet Approved
OsimertinibThe serum concentration of Deflazacort can be increased when it is combined with Osimertinib.Approved
OxandroloneDeflazacort may increase the fluid retaining activities of Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Deflazacort.Approved
Oxolinic acidThe risk or severity of adverse effects can be increased when Deflazacort is combined with Oxolinic acid.Experimental
OxymetholoneDeflazacort may increase the fluid retaining activities of Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Deflazacort.Approved, Withdrawn
PalbociclibThe serum concentration of Deflazacort can be increased when it is combined with Palbociclib.Approved
ParaoxonThe risk or severity of adverse effects can be increased when Deflazacort is combined with Paraoxon.Experimental
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Deflazacort.Approved
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Deflazacort.Investigational
PazufloxacinThe risk or severity of adverse effects can be increased when Deflazacort is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when Deflazacort is combined with Pefloxacin.Approved
PentobarbitalThe metabolism of Deflazacort can be increased when combined with Pentobarbital.Approved, Vet Approved
PhenobarbitalThe metabolism of Deflazacort can be increased when combined with Phenobarbital.Approved
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Deflazacort.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Deflazacort.Approved, Vet Approved
Phenylbutyric acidThe therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with Deflazacort.Approved, Investigational
PhenytoinThe metabolism of Deflazacort can be increased when combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe risk or severity of adverse effects can be increased when Deflazacort is combined with Physostigmine.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Deflazacort.Approved, Investigational
Pipemidic acidThe risk or severity of adverse effects can be increased when Deflazacort is combined with Pipemidic acid.Experimental
PiretanideDeflazacort may increase the hypokalemic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Deflazacort.Approved, Investigational
Piromidic acidThe risk or severity of adverse effects can be increased when Deflazacort is combined with Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Deflazacort.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Deflazacort.Experimental
Polyestradiol phosphateThe serum concentration of Deflazacort can be increased when it is combined with Polyestradiol phosphate.Approved
PolythiazideDeflazacort may increase the hypokalemic activities of Polythiazide.Approved
PosaconazoleThe metabolism of Deflazacort can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Deflazacort.Experimental, Investigational
PrimidoneThe metabolism of Deflazacort can be increased when combined with Primidone.Approved, Vet Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Deflazacort.Experimental
PromestrieneThe serum concentration of Deflazacort can be increased when it is combined with Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Deflazacort.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Deflazacort.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Deflazacort.Experimental
PrulifloxacinThe risk or severity of adverse effects can be increased when Deflazacort is combined with Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Deflazacort.Investigational
PyridostigmineThe risk or severity of adverse effects can be increased when Deflazacort is combined with Pyridostigmine.Approved
QuinestrolThe serum concentration of Deflazacort can be increased when it is combined with Quinestrol.Approved
QuinethazoneDeflazacort may increase the hypokalemic activities of Quinethazone.Approved
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Deflazacort.Approved
RanolazineThe metabolism of Deflazacort can be decreased when combined with Ranolazine.Approved, Investigational
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Deflazacort.Withdrawn
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Deflazacort.Approved, Experimental, Investigational
RifabutinThe metabolism of Deflazacort can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Deflazacort can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Deflazacort can be increased when combined with Rifapentine.Approved
RindopepimutThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Deflazacort.Investigational
RivastigmineThe risk or severity of adverse effects can be increased when Deflazacort is combined with Rivastigmine.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Deflazacort.Investigational, Withdrawn
RoflumilastRoflumilast may increase the immunosuppressive activities of Deflazacort.Approved
RosoxacinThe risk or severity of adverse effects can be increased when Deflazacort is combined with Rosoxacin.Approved, Investigational
Rotavirus VaccineThe therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Deflazacort.Approved
Rubella virus vaccineThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Deflazacort.Approved
RufloxacinThe risk or severity of adverse effects can be increased when Deflazacort is combined with Rufloxacin.Experimental
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Deflazacort.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Deflazacort.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Deflazacort.Approved
SaquinavirThe metabolism of Deflazacort can be decreased when combined with Saquinavir.Approved, Investigational
SecoisolariciresinolThe serum concentration of Deflazacort can be increased when it is combined with Secoisolariciresinol.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Deflazacort.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Deflazacort.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Deflazacort.Investigational
SildenafilThe metabolism of Deflazacort can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Deflazacort can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Deflazacort can be increased when it is combined with Simeprevir.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Deflazacort.Approved
SitafloxacinThe risk or severity of adverse effects can be increased when Deflazacort is combined with Sitafloxacin.Experimental, Investigational
Sodium bicarbonateThe bioavailability of Deflazacort can be decreased when combined with Sodium bicarbonate.Approved
SparfloxacinThe risk or severity of adverse effects can be increased when Deflazacort is combined with Sparfloxacin.Approved, Investigational
SRP 299The therapeutic efficacy of SRP 299 can be decreased when used in combination with Deflazacort.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Deflazacort.Investigational
St. John's WortThe serum concentration of Deflazacort can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StanozololDeflazacort may increase the fluid retaining activities of Stanozolol.Approved, Vet Approved
StiripentolThe serum concentration of Deflazacort can be increased when it is combined with Stiripentol.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Deflazacort.Approved
SulfisoxazoleThe metabolism of Deflazacort can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Deflazacort.Approved
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Deflazacort.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Deflazacort.Experimental
Synthetic Conjugated Estrogens, AThe serum concentration of Deflazacort can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Deflazacort can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrineThe risk or severity of adverse effects can be increased when Deflazacort is combined with Tacrine.Investigational, Withdrawn
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Deflazacort.Approved, Investigational
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Deflazacort.Investigational
TecemotideThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Deflazacort.Investigational
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Deflazacort.Approved, Withdrawn
TelithromycinThe metabolism of Deflazacort can be decreased when combined with Telithromycin.Approved
TemafloxacinThe risk or severity of adverse effects can be increased when Deflazacort is combined with Temafloxacin.Withdrawn
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Deflazacort.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Deflazacort.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Deflazacort.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Deflazacort.Approved
TestosteroneDeflazacort may increase the fluid retaining activities of Testosterone.Approved, Investigational
Testosterone PropionateDeflazacort may increase the fluid retaining activities of Testosterone Propionate.Approved, Vet Approved
TG4010The therapeutic efficacy of TG4010 can be decreased when used in combination with Deflazacort.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Deflazacort.Approved
TiboloneThe serum concentration of Deflazacort can be increased when it is combined with Tibolone.Approved, Investigational
TiclopidineThe metabolism of Deflazacort can be decreased when combined with Ticlopidine.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Deflazacort.Investigational
TocilizumabThe serum concentration of Deflazacort can be decreased when it is combined with Tocilizumab.Approved
TofacitinibDeflazacort may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Deflazacort.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Deflazacort.Approved
TorasemideDeflazacort may increase the hypokalemic activities of Torasemide.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Deflazacort.Approved, Investigational
TrastuzumabTrastuzumab may increase the neutropenic activities of Deflazacort.Approved, Investigational
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Deflazacort.Experimental
TrichlorfonThe risk or severity of adverse effects can be increased when Deflazacort is combined with Trichlorfon.Vet Approved
TrichlormethiazideDeflazacort may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Deflazacort.Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Deflazacort.Approved
TromethamineThe bioavailability of Deflazacort can be decreased when combined with Tromethamine.Approved
TrovafloxacinThe risk or severity of adverse effects can be increased when Deflazacort is combined with Trovafloxacin.Approved, Investigational, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when Deflazacort is combined with Tubocurarine.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Deflazacort.Investigational, Withdrawn
VenlafaxineThe metabolism of Deflazacort can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Deflazacort can be decreased when combined with Verapamil.Approved
VoriconazoleThe metabolism of Deflazacort can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinDeflazacort may increase the anticoagulant activities of Warfarin.Approved
Yellow fever vaccineThe therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Deflazacort.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Deflazacort.Approved, Investigational
ZeranolThe serum concentration of Deflazacort can be increased when it is combined with Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Deflazacort.Approved, Investigational, Withdrawn
ZiprasidoneThe metabolism of Deflazacort can be decreased when combined with Ziprasidone.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Deflazacort.Withdrawn
Zoster vaccineThe therapeutic efficacy of Zoster vaccine can be decreased when used in combination with Deflazacort.Approved
Food Interactions
Not Available

References

General References
  1. Mollmann H, Hochhaus G, Rohatagi S, Barth J, Derendorf H: Pharmacokinetic/pharmacodynamic evaluation of deflazacort in comparison to methylprednisolone and prednisolone. Pharm Res. 1995 Jul;12(7):1096-100. [PubMed:7494809]
  2. Nayak S, Acharjya B: Deflazacort versus other glucocorticoids: a comparison. Indian J Dermatol. 2008;53(4):167-70. doi: 10.4103/0019-5154.44786. [PubMed:19882026]
  3. Ding W, Ding L, Li WB, Pan H, Lin HD: [Pharmacokinetics of deflazacort tablets in healthy Chinese volunteers]. Yao Xue Xue Bao. 2014 Jun;49(6):921-6. [PubMed:25212041]
  4. FDA label [Link]
External Links
KEGG Drug
D03671
PubChem Compound
189821
PubChem Substance
347828252
ChemSpider
164861
ChEBI
135720
ChEMBL
CHEMBL1201891
Wikipedia
Deflazacort
ATC Codes
H02AB13 — Deflazacort

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedBasic ScienceDuchenne's Muscular Dystrophy (DMD)1
1CompletedBasic ScienceHepatic Impairment1
1CompletedBasic ScienceImpaired Renal Function1
1CompletedOtherHealthy Volunteers1
1CompletedTreatmentDuchenne's Muscular Dystrophy (DMD)1
1CompletedTreatmentHealthy Volunteers1
2, 3CompletedTreatmentDysferlinopathy / LGMD2B / Miyoshi Myopathy1
3Active Not RecruitingTreatmentDuchenne's Muscular Dystrophy (DMD)1
Not AvailableAvailableNot AvailableDuchenne's Muscular Dystrophy (DMD)1
Not AvailableRecruitingNot AvailableIgA Nephropathy / Immunosuppressive Treatment / Proteinuria in Nephrotic Range1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
SuspensionOral22.75 mg/mL
TabletOral18 mg/1
TabletOral30 mg/1
TabletOral36 mg/1
TabletOral6 mg/1
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0175 mg/mLALOGPS
logP2.56ALOGPS
logP1.8ChemAxon
logS-4.4ALOGPS
pKa (Strongest Acidic)14.74ChemAxon
pKa (Strongest Basic)0.48ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area102.26 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity117.12 m3·mol-1ChemAxon
Polarizability46.79 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins and derivatives. These are steroids with a structure based on a hydroxylated prostane moiety.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Pregnane steroids
Direct Parent
Gluco/mineralocorticoids, progestogins and derivatives
Alternative Parents
20-oxosteroids / 11-beta-hydroxysteroids / 3-oxo delta-1,4-steroids / Delta-1,4-steroids / Alpha-acyloxy ketones / Oxazolines / Secondary alcohols / Imidoesters / Cyclic ketones / Cyclic alcohols and derivatives
show 9 more
Substituents
Progestogin-skeleton / 20-oxosteroid / 3-oxo-delta-1,4-steroid / 3-oxosteroid / Hydroxysteroid / Oxosteroid / 11-beta-hydroxysteroid / 11-hydroxysteroid / Delta-1,4-steroid / Alpha-acyloxy ketone
show 24 more
Molecular Framework
Aliphatic heteropolycyclic compounds
External Descriptors
Not Available

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Substrate
General Function
Carboxylic ester hydrolase activity
Specific Function
Not Available
Gene Name
CES1A1a
Uniprot ID
Q6LAP9
Uniprot Name
Carboxylesterase
Molecular Weight
1908.25 Da

Drug created on October 20, 2016 15:00 / Updated on November 09, 2017 04:59